

A splicing variant of *TERT* identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

Alice W. Lee<sup>1</sup>, Ashley Bomkamp<sup>2</sup>, Elisa V. Bandera<sup>3</sup>, Allan Jensen<sup>4</sup>, Susan J. Ramus<sup>5</sup>, Marc T. Goodman<sup>6,7</sup>, Mary Anne Rossing<sup>8,9</sup>, Francesmary Modugno<sup>10-12</sup>, Kirsten B. Moysich<sup>13</sup>, Jenny Chang-Claude<sup>14,15</sup>, Anja Rudolph<sup>14</sup>, Aleksandra Gentry-Maharaj<sup>16</sup>, Kathryn L. Terry<sup>17,18</sup>, Simon A. Gayther<sup>19,20</sup>, Daniel W. Cramer<sup>17,18</sup>, Jennifer A. Doherty<sup>21</sup>, Joellen M. Schildkraut<sup>22</sup>, Susanne K. Kjaer<sup>4,23</sup>, Roberta B. Ness<sup>24</sup>, Usha Menon<sup>16</sup>, Andrew Berchuck<sup>25</sup>, Bhramar Mukherjee<sup>2,26</sup>, Lynda Roman<sup>27</sup>, Paul D. Pharoah<sup>28,29</sup>, Georgia Chenevix-Trench<sup>30</sup>, Sara Olson<sup>31</sup>, Estrid Hogdall<sup>4,32</sup>, Anna H. Wu<sup>1</sup>, Malcolm C. Pike<sup>1,31</sup>, Daniel O. Stram<sup>1</sup>, Celeste Leigh Pearce<sup>1,2</sup> for the Ovarian Cancer Association Consortium

<sup>1</sup> Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; <sup>2</sup> Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; <sup>3</sup> Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>4</sup> Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; <sup>5</sup> University of New South Wales, Sydney, Australia; <sup>6</sup> Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; <sup>7</sup> Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; <sup>8</sup> Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>9</sup> Department of Epidemiology, University of Washington, Seattle, WA, USA; <sup>10</sup> Department of Obstetrics, Gynecology, and

Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>11</sup> Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; <sup>12</sup> Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; <sup>13</sup> Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA; <sup>14</sup> Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>15</sup> University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; <sup>16</sup> Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom; <sup>17</sup> Obstetrics and Gynecology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; <sup>18</sup> Harvard T.H. Chan School of Public Health, Boston, MA, USA; <sup>19</sup> Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; <sup>20</sup> Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; <sup>21</sup> Department of Epidemiology, The Geisel School of Medicine at Dartmouth, Hanover, NH, USA; <sup>22</sup> Department of Public Health Sciences, The University of Virginia, Charlottesville, VA, USA; <sup>23</sup> Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; <sup>24</sup> University of Texas School of Public Health, Houston, TX, USA; <sup>25</sup> Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA; <sup>26</sup> Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA; <sup>27</sup> Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; <sup>28</sup> Department of Public Health and Primary Care, Center for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK; <sup>29</sup> Department of

Oncology, Center for Cancer Genetic Epidemiology, University of Cambridge, University of Cambridge, Cambridge, UK; <sup>30</sup> Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; <sup>31</sup> Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>32</sup> Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

## **SHORT TITLE**

GxE interactions with estrogen therapy in ovarian cancer

## **KEYWORDS**

gene-environment interactions; ovarian cancer; hormone therapy; estrogen; SNPs

## **CORRESPONDING AUTHOR**

Celeste Leigh Pearce, PhD, 1415 Washington Heights, SPH Tower Office #4642, Ann Arbor, MI 48109-2029. Phone: 734-764-3835, Fax: 734-764-3192. [lpearce@umich.edu](mailto:lpearce@umich.edu)

## **ABBREVIATIONS USED**

ET = estrogen-alone therapy

OCAC = Ovarian Cancer Association Consortium

HT = hormone therapy

NHANES = National Health and Nutrition Examination Survey

GWAS = genome-wide association study

OC = oral contraceptive

SNP = single nucleotide polymorphism

COGS = Collaborative Oncological Gene-environment Study

LAMP = Local Ancestry in Admixed Populations

OR = odds ratio

CI = confidence interval

LRT = likelihood ratio test

ICR = interaction contrast ratio

## **ARTICLE CATEGORY**

Cancer Epidemiology

## **NOVELTY AND IMPACT**

This is the first study to present evidence of statistical interactions between postmenopausal estrogen-alone therapy use and confirmed ovarian cancer susceptibility alleles on risk of serous and endometrioid ovarian cancer, suggesting effects that may not be independent. Of particular interest is the interaction with rs10069690, a functional variant located in *TERT*, a gene involved in the formation of the enzyme telomerase and whose expression is upregulated by estrogen.

## **CONFLICT OF INTEREST DISCLOSURES**

Dr. Usha Menon owns shares of Abcodia Ltd, a University College London spin-out company with an interest in biomarkers and ovarian cancer screening.

## ABSTRACT

Menopausal estrogen-alone therapy (ET) is a well-established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome-wide association studies. The interplay among these loci, ET use, and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases, and 4,051 controls across 10 case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non-users separately and to test for statistical interaction. A splicing variant in *TERT*, rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer ( $p_{\text{int}}=0.013$ ). ET users carrying the T allele had a 51% increased risk of disease (OR=1.51, 95% CI 1.19-1.91), which was stronger for long-term ET users of 10+ years (OR=1.85, 95% CI 1.28-2.66,  $p_{\text{int}}=0.034$ ). Non-users showed essentially no association (OR=1.08, 95% CI 0.96-1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype ( $p_{\text{int}}=0.021$  and  $p_{\text{int}}=0.037$ , respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow-up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci.

## **INTRODUCTION**

The etiology of ovarian carcinoma (ovarian cancer) is influenced by several hormonal factors, including menopausal hormone therapy (HT) use. Approximately five million women in the United States currently use HT, and according to the National Health and Nutrition Examination Survey (NHANES) in 2010, the most commonly used type of HT among women aged 40 years and older is estrogen-alone therapy (ET) (1,2). ET is a well-established risk factor for serous and endometrioid ovarian cancer (2-4). Most recently, Lee et al demonstrated that use of ET postmenopausally was associated with a 57% and 82% increased risk of serous and endometrioid ovarian cancer, respectively (5); the meta-analysis by the Collaborative Group on Epidemiological Studies of Ovarian Cancer showed these histotype effects as well (2).

Ovarian cancer also has a strong genetic component. A large part is attributable to high-penetrance susceptibility mutations, but common variants identified using genome-wide association studies (GWASs) play important roles as well. There are currently 18 confirmed ovarian cancer common susceptibility loci that explain approximately 3.9% of the disease's excess familial risk (6-13). Each of these common variants is associated with extremely modest relative risk estimates, but it is possible that interactions between non-genetic and genetic risk factors exist, thereby putting some women at higher risk.

Pearce et al previously examined the interactive effects between six GWAS-identified common variants and five well-accepted non-genetic risk factors: first-degree family history of ovarian cancer, tubal ligation, parity, oral contraceptive (OC) use, and personal history of endometriosis (14). However, menopausal ET, which has consistently been shown to be associated with risk of serous and endometrioid ovarian cancer (2,5), was not included in these analyses. Using data from the Ovarian Cancer Association Consortium (OCAC), we have

evaluated potential statistical interactions between menopausal ET use and the 18 confirmed ovarian cancer common susceptibility alleles. To our knowledge, this is the first study to investigate the interactions between menopausal ET use and ovarian cancer susceptibility loci on disease risk.

## **MATERIALS AND METHODS**

All studies included in this analysis had approval from ethics committees and written informed consent was obtained from all study participants.

### **Study Populations**

A total of 10 case-control studies participating in the OCAC (<http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/index.html>) were included in this analysis, with seven in the United States and three in Europe. Specific details for each of these studies have been published elsewhere (15-25), but their main study characteristics are presented in Table 1.

We had a total of 5,403 serous and endometrioid cases and 13,337 controls across the 10 OCAC studies; only serous and endometrioid cases were included as most studies have shown that only these histotypes are significantly associated with ET use (2,5,26). However, only a proportion of these women had genetic data available, leaving us with 3,855 cases and 9,593 controls. Further exclusions included the following: women who were less than 50 years of age at reference date, which was typically the date of diagnosis for cases and the date of interview for controls, (871 cases and 2,532 controls), had past diagnoses of cancer (other than non-melanoma skin cancer) (398 cases and 887 controls), had unknown or missing HT information (171 cases

and 365 controls), or had used HT in a combined estrogen-progestin form (664 cases and 1,758 controls). Hence, our final dataset included 1,414 serous cases, 337 endometrioid cases, and 4,051 controls.

### Genotype Data

To date, 18 confirmed, genome-wide significant ovarian cancer susceptibility loci ( $p \leq 5.0 \times 10^{-8}$ ) have been identified (6-13). However, subsequent fine mapping efforts have shown that in some instances, the originally published best “hit” in the confirmed region was no longer the most strongly associated single nucleotide polymorphism (SNP). Table 2 presents the originally published SNPs and, where applicable, the current best hits, which we used in the analysis presented here (6).

Details regarding the genetic data have been previously described (9). Briefly, existing genotype data from three GWASs, their replication efforts, and two large-scale arrays (the Collaborative Oncological Gene-Environment Study (iCOGS) and the Exome chip) were combined with data from the April 2012 release of the 1000 Genomes Project and imputation using the program IMPUTE2 (27) was carried out for all OCAC participants. Subjects from two studies, NCO and NEC, were split into two analytic sets based on the varying scope of genotype data (genome-wide versus array) available for imputation. This resulted in a total of 12 analytic sets for analysis (see Table 1 footnote).

### Exposure and Covariate Data

Self-completed questionnaires and phone or in-person interviews were used to collect information on HT use and other potential confounding variables including age, OC use, parity,



hysterectomy, tubal ligation, endometriosis, and education. Given that use of ET increases risk of endometrial cancer in women with intact uteri (28), the majority of ET users were hysterectomized and hence, their true age at menopause was unknown. We therefore assumed that all women in our analysis had an age at menopause of 50, which is the average age at menopause for women in the Western world (29).

Given the importance of menopause to ovarian cancer etiology, the effects of ET use prior to menopause when endogenous estrogen levels are naturally high could be inherently different from its effects after menopause (30). Therefore, we only considered women as ET users if they used ET after age 50 for at least one year. Non-users were women who had never used ET after age 50 (including women who only used ET before age 50) or had only used ET after age 50 for less than one year as the effect of such short-term use is likely to be minimal. However, a sensitivity analysis was conducted using a true “never” user baseline group, and the results did not change. Duration of postmenopausal ET use was assessed in the following categories: 1 to <5 years, 5 to <10 years, and 10+ years.

### Statistical Analysis

All models were conditioned on analytic set, five-year age category (50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years), and genetic ancestry (European, Asian, African, and other) as determined by the program LAMP (Local Ancestry in Admixed Populations) (31). Women with >90% European ancestry were classified as European, >80% Asian or African ancestry were classified as Asian or African, respectively, and those with mixed ancestry were classified as other (9). In addition, all models were adjusted for OC use (never [including <1 year of use], 1 to <2 years, 2 to <5 years, 5 to <10 years, and 10+ years), parity (never, 1 birth, 2+ births),

hysterectomy (yes/no), endometriosis (yes/no), tubal ligation (yes/no), and education (less than high school, high school, some college, college graduate or higher) since they were judged to be potentially important confounders a priori. Missing categories were created for women missing any of the covariates so their data could be included in the analysis. Data on hysterectomy status was not available from all sites, but sensitivity analyses showed that hysterectomy status did not substantially impact the estimates for ET or any of the SNPs.

Weighted genetic risk scores, which took into account the 18 confirmed SNPs simultaneously, were calculated by taking the beta coefficients for each SNP's association with risk of serous and endometrioid ovarian cancer using all OCAC studies in which genotype data was available (43 OCAC studies, which included 18,174 cases and 26,134 controls (9)) and multiplying them by the genotype value (0-2) for each subject (i.e., beta coefficients were derived from a much larger dataset). These values for the 18 SNPs were then summed to obtain each individual's total risk score, which was then categorized into quartiles according to the distribution in controls for ease of interpretation.

Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for the main effect association between each SNP or genetic risk score quartile and disease risk using conditional logistic regression. This was done for the serous and endometrioid histotypes separately. Previous analyses that evaluated ET's main effect on risk of serous ovarian cancer showed no difference by grade so all serous cases were combined in our analysis (5). These genetic associations were further stratified by whether or not ET was used after age 50. Because these gene-environment interaction analyses were primarily focused on understanding disease etiology, we tested for statistical interaction (i.e., departure from a multiplicative model) between the 18 ovarian cancer susceptibility loci or genetic risk score and ET use on risk of serous and

endometrioid ovarian cancer using the likelihood ratio test (LRT) comparing models with and without interaction terms (32). A similar approach was used to analyze the effect of duration categories of ET use for the associations showing a significant interaction with ever/never ET use. For completeness, we also assessed interactions on the additive scale by calculating interaction contrast ratios (ICRs) and 95% CIs for the ICRs; ICR values greater than zero with 95% CIs that excluded zero indicated greater than additive effects.

All p-values reported were two-sided and considered significant at  $p \leq 0.05$ . An adjusted p-value that factored in the number of tests for interaction conducted was considered as well. All analyses were performed using STATA release 14.0.

## **RESULTS**

A total of 5,802 women were included in these analyses, with 1,414 serous cases, 337 endometrioid cases, and 4,051 controls (Table 1). Approximately 13.6%, 20.0%, and 15.1% of the controls, serous cases, and endometrioid cases, respectively, reported using ET after age 50. In addition, 18 confirmed ovarian cancer SNPs were investigated here and their characteristics are presented in Table 2. For nine of the 18 SNPs, their corresponding previously reported best hits are listed as well (Table 2).

Although the main effects of each of the 18 SNPs have been previously published, Table 3 shows their main effects as well as the effects of genetic risk score in quartiles with serous ovarian cancer. There was a statistically significant interaction between ET use and the T allele of rs10069690 on chromosome 5 on risk of serous ovarian cancer that showed departure from both additivity and multiplicativity (ICR=0.55, 95% CI 0.16-0.94;  $p_{\text{int}}$  for LRT=0.013) (Table 3). While the T allele of rs10069690 was associated with a 51% increased risk of serous ovarian

cancer among ET users (OR=1.51, 95% CI 1.19-1.91), there was essentially no risk among non-users (OR=1.08, 95% CI 0.96-1.21).

Table 4 presents the same information as Table 3, but for the endometrioid histotype. Two statistically significant interactions between the genetic variants rs7207826 and rs56318008 and ET use on risk of disease that showed departure from multiplicativity were observed ( $p_{\text{int}}$  for LRT=0.021 and  $p_{\text{int}}$  for LRT=0.037, respectively) (Table 4). Rs7207826 (T allele) on chromosome 17 was positively associated with the endometrioid histotype among non-users of ET (OR=1.32, 95% CI 1.09-1.61), but showed a decreased risk of disease among ET users (OR=0.71, 95% CI 0.43-1.18). Similarly, non-users of ET carrying the C allele for rs56318008 on chromosome 1 showed an increased risk of endometrioid ovarian cancer (OR=1.53, 95% CI 1.21-1.92) whereas ET users showed a decreased risk (OR=0.82, 95% CI 0.46-1.45). Genetic risk score did not appear to interact with ET use on risk of either histotype ( $p_{\text{int}}$  for LRT=0.52 for serous,  $p_{\text{int}}$  for LRT=0.25 for endometrioid) (Tables 3 and 4).

For each of the three SNPs that showed a statistically significant interaction with postmenopausal ET use on serous or endometrioid ovarian cancer risk at a  $p \leq 0.05$  level on a multiplicative scale, the association between the SNP and risk of disease was assessed by duration of ET use. Rs7207826 and rs56318008 did not have significant interactions with duration for endometrioid ovarian cancer ( $p_{\text{int}}$  for LRT=0.18 and  $p_{\text{int}}$  for LRT=0.087, respectively). However, rs10069690 did have a significant interaction for serous ovarian cancer ( $p_{\text{int}}$  for LRT=0.034); women who carried the T allele and had used ET for 10+ years had close to a two-fold increased risk relative to non-users of ET who carried the C (reference) allele (OR=1.85, 95% CI 1.28-2.66) (Table 5).

With 18 SNPs plus a genetic risk score for two histotypes and three additional duration interactions, we conducted a total of 41 tests for interaction in the analyses presented here. Four of these interactions were considered statistically significant at a  $p \leq 0.05$  level. Although this is twice as many interaction associations as would be expected by chance at the  $p \leq 0.05$  level, none of them met a Bonferroni threshold for multiple comparisons of  $p = 1.22 \times 10^{-3}$  ( $0.05/41$  tests).

## DISCUSSION

We have shown evidence of statistical interactions between postmenopausal ET use and three confirmed ovarian cancer susceptibility alleles with risk of serous and endometrioid ovarian cancer. Although none of the interactions we report here remained significant after adjusting for multiple comparisons, these results may still be relevant as they could contribute to our understanding of the mechanism of action for these loci.

The most significant and biologically plausible interaction identified was rs10069690 for serous ovarian cancer, a SNP whose main effect has only been observed for the serous histotype (13). Rs10069690 is located in the *TERT-CLPTMIL* region of chromosome 5p15.33, a multi-cancer susceptibility locus that encodes the reverse transcriptase subunit (hTERT) of telomerase, an enzyme known to help maintain telomere length and integrity. Telomere shortening is often associated with genetic instability and hence increased risk of cancer and death, but telomerase has been shown to counteract this process, making the expression of *TERT* important in preventing tumorigenesis. Evidence has suggested that sex steroid hormones, such as estrogen, may be good candidates as physiological regulators of *TERT* (33). Some findings have shown telomerase activity to be under hormonal control in estrogen-targeted tissues, including the

endometrium (34) and the ovary (35); the expression of *TERT* has been shown to be upregulated by estrogen (36,37).

Recently, Killekar et al reported rs10069690 as a likely functional SNP since its risk-associated T allele was shown to result in the co-production of full length-hTERT as well as an alternatively spliced transcript, which encodes a catalytically inactive protein that inhibits telomerase activity; this was thought to be due to a dominant negative effect of the protein since telomerase exists as a dimer and its catalytic activity requires both hTERT active sites to be functional (38). The decreased enzymatic activity may result in shorter telomeres, which could lead to an increased risk of genetic instability and subsequent carcinogenesis. Given the evidence suggesting estrogen's role in the transcriptional regulation of hTERT, the elevated risk of serous ovarian cancer may be attributable to the inhibition of telomerase activity from higher levels of estrogen with prolonged ET use (OR=1.85, 95% CI 1.28-2.66 for 10+ years).

Cancer cells have also been shown to activate telomerase to stabilize telomeres for continued proliferation and cellular immortalization. However, from this perspective, the inhibition of telomerase associated with rs10069690 would result in cell death of cancer cells and hence a decreased risk of disease particularly among ET users, which is contrary to our findings. Presently, it is unclear whether telomerase activation helps in the uncontrolled cellular proliferation of existing cancer cells or in the preservation of a non-malignant phenotype by maintaining the replicative longevity of ovarian cells (35). Our results appear to support the latter.

The additional two interactions observed with ET use were rs56318008 and rs7207826 for endometrioid ovarian cancer. Rs56318008 is located near *WNT4*, a gene involved in steroidogenesis (39) and implicated in GWASs for risk of endometriosis (40), an estrogen-

related gynecologic condition strongly associated with the endometrioid histotype (41).

Rs7207826 is located near *SKAPI*, a gene that does not appear to be directly related to female sex hormones and is primarily involved in T cell signaling and the regulation of the lymphocyte function-associated antigen 1 gene (*LFA-1*). It should be noted though that *WNT4* and *SKAPI* have not been shown to be the targets of risk SNPs at these loci.

Although this study is the largest of its kind, it still has a modest sample size in which to attempt to discover interactions. In addition, the self-reported nature of the exposure and covariate data used could be considered a limitation. However, studies have shown high agreement between information collected using interviews versus records for HT use (42) as well as other reproductive factors (43,44). Our results may be due to chance as these interactions do not survive correction for multiple hypothesis testing, but the fact that these are confirmed susceptibility alleles adds support to our findings. Given the role of estrogen in *TERT* activation and expression, rs10069690 is of particular interest. From a biological standpoint, this SNP appears to affect telomerase activity and hence, telomere maintenance, actions that could promote tumorigenesis if improperly regulated (38). Although we cannot rule out that the observed interaction may be due to a SNP in the region that is in linkage disequilibrium with rs10069690, the fact that rs10069690 is functional with biological plausibility supporting its interaction with ET use makes it a strong candidate. The other two SNPs implicated in this analysis are intriguing as well in that they are confirmed ovarian cancer susceptibility loci. However, as previously mentioned, the target genes for these SNPs are unknown and hence their relevance remains uncertain at this time.

Our results highlight the complexity of ovarian cancer etiology. In addition, they provide evidence that the roles of ET and the 18 ovarian cancer common variants in ovarian

carcinogenesis may be beyond their independent effects. This is the first study, to our knowledge, to suggest potential gene-environment interactions in ovarian cancer in the context of HT use with confirmed susceptibility alleles. These findings, if replicated, may be critical for future risk prediction modeling.



## **ACKNOWLEDGEMENTS**

We thank all the individuals who took part in this study and all the researchers, clinicians and technical and administrative staff who have made possible the many studies contributing to this work. In particular, we thank: L. Paddock, M. King, L. Rodriguez-Rodriguez, A. Samoila, and Y. Bensman (NJO); I. Jacobs, M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan, C. Karpinskyj, and J. Ford (UKO); A. Amin Al Olama, J. Dennis, E. Dicks, K. Michilaidou, K. Kuchenbaker (COGS).

## **FUNDING SUPPORT**

The scientific development and funding for this project were funded by the following: the US National Cancer Institute (R01 CA076016); the COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 HEALTH F2 2009-223175); the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative (U19-CA148112); the Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07).

It was also supported by the National Institutes of Health (P30 CA14089, R01 CA61132, P01 CA17054, N01 PC67010, R03 CA113148, N01 CN025403, and R03 CA115195 [USC], K07 CA095666, R01 CA83918, K22 CA138563, and P30 CA072720 [NJO], R01 CA112523 and R01 CA87538 [DOV], R01 CA58598, N01 PC67001, and N01 CN55424 [HAW], R01 CA76016 [NCO], R01 CA54419 and P50 CA105009 [NEC], R01 CA61107 [MAL], and R01 CA095023, R01 CA126841, M01 RR000056, P50 CA159981, and K07 CA80668 [HOP]); California Cancer Research Program (0001389V20170 and 2110200 [USC]); German Federal

Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research (01GB9401 [GER]); German Cancer Research Centre (GER); Danish Cancer Society (94 222 52 [MAL]); Mermaid I [MAL]; Eve Appeal/Oak Foundation (UKO); Cancer Institute of New Jersey (NJO); the National Institute for Health Research University College London Hospitals Biomedical Research Centre (UKO); US Army Medical Research and Materiel Command (W81XWH-10-1-02802 [NEC], DAMD17-02-1-0669 [HOP], and DAMD17-02-1-0666 [NCO]); Roswell Park Alliance Foundation (HOP); the National Health and Medical Research Council (for G.C.T.); and the National Institute of Environmental Health Sciences (T32 ES013678 for A.W.L.).

In addition, U.M. received research funding from Abcodia Ltd, a University College London spin-out company with an interest in biomarkers and ovarian cancer screening. Research reported in this publication was also partially supported by NCI award number P30 CA008748 (PI: Thompson) to Memorial Sloan Kettering Cancer Center. It was also supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA046592. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## REFERENCES

1. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. *Obstet Gynecol* 2012; 120: 595-603
2. Collaborative Group On Epidemiological Studies Of Ovarian C, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet* 2015; 385: 1835-1842
3. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. *Cancer* 2009; 115: 531-539
4. Beral V, Million Women Study C, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2007; 369: 1703-1710
5. Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL, Ovarian Cancer Association C. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstet Gynecol* 2016; 127: 828-836
6. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jonson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, Embrace, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, Collaborators GS, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomaki K, Nevanlinna H, Collee JM, Rookus MA, Oosterwijk JC, Breast Cancer Family R, Tihomirova L, Tung N, Hamann U, Isacs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, Hebon, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, Investigators KC, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Australian Cancer S, Australian Ovarian Cancer Study G, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-

- Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Durst M, Hillemanns P, Dork T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Borge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permut-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G, Consortium of Investigators of Modifiers of B, Brca. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet* 2015; 47: 164-171
7. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeny LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moysich KB, Baker JA, Modugno F, Heikkinen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Durst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Australian Ovarian Cancer Study G, Australian Cancer S, Ovarian Cancer Association C, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet* 2010; 42: 880-884
8. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeny LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dork T,

- Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Wellcome Trust Case-Control C, Beesley J, Webb PM, Australian Cancer S, Australian Ovarian Cancer Study G, Ovarian Cancer Association C, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Durst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, Ovarian Cancer Association C. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 2010; 42: 874-879
9. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Australian Cancer S, Australian Ovarian Cancer Study G, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gijyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Hogdall E, Hogdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemenev LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubinski J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Peltari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* 2013; 45: 362-370, 370e361-362
10. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Consortium P, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van

- Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlov I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeny LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Hogdall CK, Hogdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Durst M, du Bois A, Dork T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Australian Ovarian Cancer Study G, Australian Cancer S, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun* 2013; 4: 1628
11. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Australian Cancer S, Australian Ovarian Cancer Study G, Ovarian Cancer Association C, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD, Gayther SA. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 2009; 41: 996-1000
12. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Australian Cancer S, Australian Ovarian Cancer S, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Consortium of Investigators of Modifiers of B, Cook LS, Couch FJ,

- Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Gorski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Hogdall CK, Hogdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun* 2013; 4: 1627
13. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F, Australian Cancer S, Australian Ovarian Cancer S, Kathleen Cuninghame Foundation Consortium for Research into Familial Breast C, Gene Environment I, Breast C, Swedish Breast Cancer S, Hereditary B, Ovarian Cancer Research Group N, Epidemiological study of B, Carriers BM, Genetic Modifiers of Cancer Risk in BMC, Vergote I, Lambrechts S, Despierre E, Risch HA, Gonzalez-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guenel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Durst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dork T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Hogdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H,

Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlov I, Blomqvist C, Rodriguez-Rodriguez L, Aittomaki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeny LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Hogdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Muller H, Arndt V, Labreche F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Bruning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkas K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsana P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilias G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collee JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet* 2013; 45: 371-384, 384e371-372



14. Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM, for Australian Cancer S, Australian Ovarian Cancer Study G, Chenevix-Trench G, Jordan SM, Stram DA, Chang-Claude J, Hein R, Nickels S, Lurie G, Thompson PJ, Carney ME, Goodman MT, Moysich K, Hogdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Vierkant RA, Weber RP, Ziogas A, Anton-Culver H, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Brinton L, Wentzensen N, Lissowska J, Garcia-Closas M, Massuger LF, Kiemenev LA, Van Altena AM, Aben KK, Berchuck A, Doherty JA, Iversen E, McGuire V, Moorman PG, Pharoah P, Pike MC, Risch H, Sieh W, Stram DO, Terry KL, Whittemore A, Wu AH, Schildkraut JM, Kjaer SK, Ovarian Cancer Association C. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 880-890
15. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. *Int J Cancer* 2001; 95: 370-374
16. Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. *J Clin Epidemiol* 2011; 64: 525-530
17. Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Palmieri RT, Cramer DW, Goodman MT. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. *Cancer Causes Control* 2010; 21: 1731-1741
18. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. *Ann Epidemiol* 2011; 21: 188-196
19. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. *Am J Epidemiol* 2008; 167: 1059-1069
20. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. *Int J Cancer* 2009; 124: 1409-1415
21. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. *Cancer Res* 2005; 65: 5974-5981
22. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. *Fertil Steril* 2004; 82: 186-195
23. Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Sun exposure and risk of epithelial ovarian cancer. *Cancer Causes Control* 2012; 23: 1985-1994
24. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. *Arch Intern Med* 2004; 164: 2253-2259
25. Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. *BMC Womens Health* 2011; 11: 40
26. Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK, Lidegaard O. Hormone therapy and different ovarian cancers: a national cohort study. *Am J Epidemiol* 2012; 175: 1234-1242

27. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. *G3 (Bethesda)* 2011; 1: 457-470
28. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995; 85: 304-313
29. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. *Am J Epidemiol* 1998; 148: 1195-1205
30. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. *Nature* 1983; 303: 767-770
31. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. *Am J Hum Genet* 2008; 82: 290-303
32. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. *Am J Epidemiol* 1980; 112: 467-470
33. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M. Estrogen activates telomerase. *Cancer Res* 1999; 59: 5917-5921
34. Kyo S, Takakura M, Kohama T, Inoue M. Telomerase activity in human endometrium. *Cancer Res* 1997; 57: 610-614
35. Liu JP, Li H. Telomerase in the ovary. *Reproduction* 2010; 140: 215-222
36. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. *Blood* 2009; 114: 2236-2243
37. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, Piaggio G, Sacchi A, Pontecorvi A, Bacchetti S, Farsetti A. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. *Mol Cell Biol* 2000; 20: 3764-3771
38. Killedar A, Stutz MD, Sobinoff AP, Tomlinson CG, Bryan TM, Beesley J, Chenevix-Trench G, Reddel RR, Pickett HA. A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase. *PLoS Genet* 2015; 11: e1005286
39. Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, Jeong JW, Lydon JP, Bagchi IC, Bagchi MK, DeMayo FJ. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. *FASEB J* 2011; 25: 1176-1187
40. Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, MacGregor S, Gordon SD, Henders AK, Martin NG, Attia J, Holliday EG, McEvoy M, Scott RJ, Kennedy SH, Treloar SA, Missmer SA, Adachi S, Tanaka K, Nakamura Y, Zondervan KT, Zembutsu H, Montgomery GW. Genome-wide association meta-analysis identifies new endometriosis risk loci. *Nat Genet* 2012; 44: 1355-1359
41. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A, Ovarian Cancer Association C. Association between endometriosis and risk of histological subtypes of

- ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 2012; 13: 385-394
42. Sandini L, Pentti K, Tuppurainen M, Kroger H, Honkanen R. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. *Menopause* 2008; 15: 282-289
  43. Glass R, Johnson B, Vessey M. Accuracy of recall of histories of oral contraceptive use. *Br J Prev Soc Med* 1974; 28: 273-275
  44. Gentry-Maharaj A, Taylor H, Kalsi J, Ryan A, Burnell M, Sharma A, Apostolidou S, Campbell S, Jacobs I, Menon U. Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMJ Open* 2014; 4: e004421

**Table 1.** Description of studies included in analysis

Study Name	Study Abbrev.	Country	Study Period	Method of Data Collection	Number of Controls <sup>a</sup>	Number of Serous Cases <sup>a</sup>	Number of Endometrioid Cases <sup>a</sup>
Disease of the Ovary and their Evaluation Study (23)	DOV	USA	2002-2009	In-person interview	547 (123)	218 (65)	53 (10)
German Ovarian Cancer Study (15)	GER	Germany	1992-1998	Self-completed questionnaire	232 (39)	66 (11)	11 (4)
Hawaii Ovarian Cancer Study (17)	HAW	USA	1994-2007	In-person interview	229 (28)	68 (13)	23 (6)
Hormones and Ovarian Cancer Prediction (18)	HOP	USA	2003-2008	In-person interview	694 (68)	168 (28)	48 (7)
Malignant Ovarian Cancer Study (24)	MAL	Denmark	1994-1999	In-person or phone interview	363 (47)	96 (11)	17 (2)
North Carolina Ovarian Cancer Study <sup>b</sup> (19)	NCO	USA	1999-2008	In-person interview	401 (70)	189 (60)	47 (10)
New England Case-Control Study of Ovarian Cancer <sup>b</sup> (21)	NEC	USA	1999-2008	In-person interview	394 (28)	211 (26)	56 (3)
New Jersey Ovarian Cancer Study (25)	NJO	USA	2002-2008	Phone interview	112 (6)	63 (3)	20 (0)
United Kingdom Ovarian Cancer Population Study (16)	UKO	United Kingdom	2006-2007	In-person interview	490 (47)	27 (1)	9 (0)
University of Southern California, Study of Lifestyle and Women's Health (20,22)	USC	USA	1993-2008	In-person interview	589 (95)	308 (65)	53 (9)
				<b>Total:</b>	4,051 (551)	1,414 (283)	337 (51)

<sup>a</sup> Number in parentheses indicates the number of postmenopausal ET users.

<sup>b</sup> Subjects were split into two different analytic sets.

**Table 2.** Characteristics of the 18 SNPs included in the analysis and their previously reported best hits

SNP	Previously Published Best Hit <sup>a</sup>	Chromosome Band	Position	Reference Allele(s)	Tested Allele <sup>b</sup>	Tested Allele Frequency <sup>c</sup>
rs58722170 (6)		1p34.3	38096421	G	C	0.15
rs10069690 (13)		5p15.33	1279790	C	T	0.35
chr10:21878831:D	rs1243180 (9)	10p12.31	21878831	CCCTTC	-	0.14
rs17329882 (6)		4q26	119949960	A	C	0.15
rs1879586	rs12942666 (12)	17q21.31	43567337	C	G	0.08
rs56318008 (6)		1p36	22470407	C	T	0.20
rs4808075	rs2363956 (7)	19p13.11	17390291	T	C	0.16
chr9:136138765:D (6)		9q34.2	136138765	CGCCCACCACTA	-	0.13
rs7207826	rs9303542 (9)	17q21.32	46500673	T	C	0.31
rs76837345	rs11782652 (9)	8q21.13	82668818	A	G	0.04
rs62274042	rs7651446 (9)	3q25.31	156435952	G	A	0.01
rs635634 (6)		9q34.2	136155000	C	T	0.14
rs3744763 (10)		17q12	36090885	G	A	0.69
chr17:29181220:I (6)		17q11.2	29181220	-	T	0.13
rs6755777	rs2072590 (8)	2q31.1	177043226	T	G	0.82
rs117224476	rs3814113 (11)	9q22.2	16907967	T	G	0.16
rs1400482	rs10088218 (8)	8q24.21	129541931	G	A	0.09
rs116133110 (6)		6q22.1	28480635	T	C	0.46

Note: chr10:21878831:D and chr17:29181220:I are listed as rs1449962376 and rs199661266, respectively, in 1000 Genomes.

<sup>a</sup> If not specified, the previously published best hit is the same as the current best hit considered.

<sup>b</sup> “-“ refers to a deletion.

<sup>c</sup> Based on 1000 Genomes for all populations. For chr9:136138765:D (rs587729126), the tested allele frequency was based on the controls in the full OCAC dataset since the SNP is not listed in 1000 Genomes.

**Table 3.** Association between each of the 18 SNPs and genetic risk score and risk of serous ovarian cancer, stratified by ET use after age 50

	Main Effect		No ET Use (N=1,131 cases/3,500 controls)		ET Use (N=283 cases/551 controls)		p-value for interaction
	OR <sup>a,b</sup>	95% CI	OR <sup>a</sup>	95% CI	OR <sup>a</sup>	95% CI	
<b>SNP</b>							
rs58722170	1.25	1.11 – 1.40	1.21	1.06 – 1.38	1.41	1.07 – 1.85	0.31
rs10069690	1.14	1.03 – 1.26	1.08	0.96 – 1.21	1.51	1.19 – 1.91	<b>0.013</b>
chr10:21878831:D	1.14	1.03 – 1.26	1.15	1.03 – 1.29	1.09	0.86 – 1.38	0.68
rs17329882	1.14	1.02 – 1.28	1.17	1.03 – 1.32	1.05	0.81 – 1.37	0.47
rs1879586	1.15	1.01 – 1.30	1.17	1.02 – 1.34	1.04	0.78 – 1.37	0.44
rs56318008	1.16	1.03 – 1.31	1.22	1.06 – 1.39	0.93	0.698 – 1.25	0.099
rs4808075	1.18	1.07 – 1.31	1.20	1.07 – 1.34	1.13	0.90 – 1.42	0.64
chr9:136138765:D	1.08	0.93 – 1.26	1.14	0.96 – 1.34	0.89	0.63 – 1.26	0.21
rs7207826	1.17	1.06 – 1.29	1.19	1.06 – 1.33	1.06	0.84 – 1.35	0.39
rs76837345	1.19	0.98 – 1.44	1.27	1.03 – 1.57	0.88	0.55 – 1.39	0.14
rs62274042	1.65	1.36 – 2.01	1.59	1.28 – 1.97	1.98	1.24 – 3.14	0.40
rs635634	1.14	1.01 – 1.29	1.16	1.01 – 1.33	1.06	0.80 – 1.40	0.56
rs3744763	0.89	0.81 – 0.97	0.89	0.80 – 0.98	0.88	0.72 – 1.09	0.97
chr17:29181220:I	0.89	0.80 – 0.99	0.88	0.78 – 0.99	0.93	0.72 – 1.19	0.71
rs6755777	0.98	0.89 – 1.09	0.98	0.88 – 1.10	0.99	0.80 – 1.24	0.94
rs117224476	0.73	0.64 – 0.84	0.76	0.65 – 0.88	0.62	0.45 – 0.85	0.26
rs1400482	0.80	0.69 – 0.92	0.81	0.69 – 0.95	0.77	0.54 – 1.09	0.79
rs116133110	0.86	0.78 – 0.95	0.87	0.78 – 0.97	0.83	0.66 – 1.04	0.69
<b>Risk score quartile</b>							
2 <sup>nd</sup> vs. 1 <sup>st</sup> quartile	1.15	0.94 – 1.41	1.18	0.95 – 1.48	0.98	0.61 – 1.59	0.52
3 <sup>rd</sup> vs. 1 <sup>st</sup> quartile	1.56	1.29 – 1.90	1.53	1.24 – 1.90	1.77	1.12 – 2.81	
4 <sup>th</sup> vs. 1 <sup>st</sup> quartile	2.26	1.87 – 2.72	2.31	1.88 – 2.85	2.00	1.30 – 3.08	

Note: OR=odds ratio, CI=confidence interval. P-values significant at a  $\leq 0.05$  level are indicated in bold.

<sup>a</sup> Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set.

<sup>b</sup> All SNP main effects show genome-wide significance ( $p \leq 5.0 \times 10^{-8}$ ) in the full OCAC dataset.

**Table 4.** Association between each of the 18 SNPs and genetic risk score and risk of endometrioid ovarian cancer, stratified by ET use after age 50

	Main Effect		No ET Use (N=286 cases/3500 controls)		ET Use (N=51 cases/551 controls)		p-value for interaction
	OR <sup>a,b</sup>	95% CI	OR <sup>a</sup>	95% CI	OR <sup>a</sup>	95% CI	
<b>SNP</b>							
rs58722170	0.95	0.76 – 1.20	0.97	0.75 – 1.25	0.87	0.50 – 1.52	0.73
rs10069690	0.98	0.81 – 1.20	0.93	0.75 – 1.16	1.32	0.82 – 2.15	0.20
chr10:21878831:D	1.08	0.89 – 1.30	1.03	0.84 – 1.27	1.30	0.81 – 2.08	0.39
rs17329882	1.07	0.87 – 1.32	1.11	0.88 – 1.39	0.90	0.52 – 1.56	0.48
rs1879586	0.97	0.76 – 1.24	0.99	0.77 – 1.29	0.83	0.46 – 1.52	0.59
rs56318008	1.40	1.13 – 1.74	1.53	1.21 – 1.92	0.82	0.46 – 1.45	<b>0.037</b>
rs4808075	1.01	0.83 – 1.22	1.02	0.83 – 1.25	0.97	0.60 – 1.56	0.84
chr9:136138765:D	0.99	0.74 – 1.31	1.03	0.76 – 1.41	0.74	0.35 – 1.55	0.41
rs7207826	1.21	1.01 – 1.45	1.32	1.09 – 1.61	0.71	0.43 – 1.18	<b>0.021</b>
rs76837345	1.25	0.89 – 1.75	1.14	0.78 – 1.68	1.69	0.83 – 3.46	0.35
rs62274042	1.12	0.75 – 1.68	1.10	0.70 – 1.70	1.34	0.47 – 3.75	0.73
rs635634	1.04	0.83 – 1.31	1.10	0.86 – 1.41	0.76	0.41 – 1.42	0.28
rs3744763	1.06	0.89 – 1.26	1.07	0.89 – 1.28	1.00	0.65 – 1.54	0.79
chr17:29181220:I	0.81	0.66 – 0.99	0.81	0.65 – 1.01	0.80	0.49 – 1.32	0.97
rs6755777	1.01	0.84 – 1.21	0.98	0.81 – 1.20	1.14	0.73 – 1.78	0.56
rs117224476	0.79	0.62 – 1.02	0.85	0.65 – 1.11	0.54	0.28 – 1.06	0.21
rs1400482	0.98	0.76 – 1.26	0.92	0.70 – 1.21	1.36	0.73 – 2.52	0.26
rs116133110	1.04	0.87 – 1.24	1.08	0.89 – 1.31	0.85	0.55 – 1.31	0.32
<b>Risk score quartile</b>							
2 <sup>nd</sup> vs. 1 <sup>st</sup> quartile	1.49	1.04 – 2.14	1.40	0.94 – 2.09	1.98	0.79 – 4.94	0.25
3 <sup>rd</sup> vs. 1 <sup>st</sup> quartile	1.69	1.18 – 2.40	1.65	1.12 – 2.42	2.04	0.80 – 5.17	
4 <sup>th</sup> vs. 1 <sup>st</sup> quartile	1.73	1.22 – 2.46	1.85	1.27 – 2.70	1.10	0.42 – 2.91	

Note: OR=odds ratio, CI=confidence interval. P-values significant at a  $\leq 0.05$  level are indicated in bold.

<sup>a</sup> Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set.

<sup>b</sup> All SNP main effects show genome-wide significance ( $p \leq 5.0 \times 10^{-8}$ ) in the full OCAC dataset.

**Table 5.** Association between rs10069690 and risk of serous ovarian cancer by duration of ET use after age 50

SNP	1 to <5 years (N=70 cases/193 controls)		5 to <10 years (N=82 cases/168 controls)		10+ years (N=131 cases/190 controls)	
	OR <sup>a</sup>	95% CI	OR <sup>a</sup>	95% CI	OR <sup>a</sup>	95% CI
rs10069690	1.41	0.90 – 2.23	1.21	1.09 – 2.32	1.85	1.28 – 2.66
p-value for interaction = 0.034						

Note: OR=odds ratio, CI=confidence interval. The reference group consists of women who did not use ET after age 50 and carried the C (reference) allele.

<sup>a</sup> Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set.